In this article, we will look at the 10 Fastest Growing NASDAQ Stocks to Buy.
High-growth stocks have once again taken center stage, and major asset managers contend that earnings momentum remains the decisive factor. In its 2026 Year-Ahead Investment Outlook, J.P. Morgan Asset Management notes that “profit growth has been impressive, tracking for four consecutive quarters of double-digit earnings growth”. The firm adds that “within stocks, we continue to see the biggest opportunities in structural rather than cyclical stories”, underscoring a preference for companies benefiting from secular tailwinds. Artificial intelligence remains a major catalyst behind this structural growth. J.P. Morgan writes that “the investment and adoption of AI continues to dominate the strength seen in U.S. economic and earnings growth”.
Vanguard’s 2026 Economic and Market Outlook echoes this constructive stance on growth, stating that “U.S. technology stocks could well maintain their momentum given the rate of investment and anticipated earnings growth.” At the same time, Vanguard cautions that “risks are growing amid this exuberance,” highlighting the need for selectivity.
Taken together, these outlooks suggest that fast-growing companies with sustained revenue acceleration and clear structural drivers remain compelling. With growth serving as the engine of returns, the focus shifts to businesses capable of compounding at elevated rates rather than merely benefiting from earnings multiple expansion. Against this backdrop, we’ll look at the 10 Fastest Growing NASDAQ Stocks to Buy.
Our Methodology
We used the Finviz screener to identify stocks that have achieved more than 50% sales growth over the past year and more than 50% growth over the past three years. We limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
10. Brookfield Asset Management Ltd. (NYSE:BAM)
On February 17, 2026, Morgan Stanley raised its price target on Brookfield Asset Management to $63 from $62 and maintained an Equal Weight rating, updating its model following the Q4 report.
Earlier in February, Brookfield Asset Management reported Q4 EPS of 47c, compared to the 44c consensus estimate. Fee-bearing capital grew to $603B, up 12% year over year, driven by record quarterly fundraising of $35B and $112B in the last year. CEO Connor Teskey said, “2025 was another record year for our business,” citing results “across each of fundraising, deployment, and monetizations.” He added that fee-bearing capital grew “to over $600B,” with “22% year-over-year growth in fee-related earnings” and “14% growth in distributable earnings.” Teskey said the company will have “key flagship strategies in the market” and a “growing suite of complementary offerings,” which supports the decision “to increase our dividend by 15%.”
The board declared a quarterly dividend of 50.25c per share, representing a 15% increase, payable on March 31 to shareholders of record as of the close of business on February 27.
Brookfield Asset Management Ltd. (NYSE:BAM) is a private equity firm specializing in acquisitions and growth capital investments, typically investing in renewable power, transition, and infrastructure sectors.
9. Hims & Hers Health, Inc. (NYSE:HIMS)
On February 24, 2026, Barclays lowered its price target on Hims & Hers Health, Inc. (NYSE:HIMS) to $25 from $48 and kept an Overweight rating on the shares. That same day, TD Cowen analyst Jonna Kim lowered the firm’s price target to $17 from $20 and maintained a Hold rating, citing near-term pressure until there is more clarity on regulatory implications around compounded injectable GLP-1s and improvement in the underlying core business momentum.
Morgan Stanley analyst Craig Hettenbach also reduced the firm’s price target to $21 from $40 and kept an Equal Weight rating. The analyst said 2026 revenue guidance “surprisingly” came in about 2% ahead of the Street view, but EBITDA guidance was about 8% below consensus, confirming concerns about increased investment.
On February 23, 2026, Hims & Hers Health reported Q4 EPS of 8c, compared to the 19c consensus estimate. Q4 revenue was $617.82M, versus consensus of $617.25M. Co-founder and CEO Andrew Dudum said, “More than 2.5 million subscribers now rely on us,” adding the company believes it is “well on our way to becoming the global leader in consumer health.” Dudum stated that in 2025 the company expanded access to care “across an expanding range of conditions,” including “launching hormone therapies and diagnostics” and “introducing Labs,” while taking steps “to grow internationally.” He added that the “continued growth and diversification of our platform” supports proactive and personalized care.
Hims & Hers Health, Inc. (NYSE:HIMS) operates a consumer-first health and wellness platform connecting consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally.
